Zonisamide
Binge Eating Disorder Associated With Obesity
Lindner Center of HOPESmall moleculePhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Binge Eating Disorder Associated With Obesity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sibutramine Yale University | Phase 4 | BBB |
Liraglutide Universiti Kebangsaan Malaysia Medical Centre | Phase 4 | BB |
Topamax University of Virginia | Phase 3 | BB |
Namenda Mclean Hospital | Phase 4 | BB |
Orlistat Yale University | Phase 4 | BB |
View all 12 →
Same molecule, other indications
Zonisamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →